Medicenna Therapeutics annual ebitda
2023
2024
2025
2026
Medicenna Therapeutics EBITDA Growth & History (MDNAF)
Medicenna Therapeutics's calculated EBITDA was −$22.3M for fiscal 2026.
View full Medicenna Therapeutics company overviewMedicenna Therapeutics annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2026 | 2026-03-31 | −$22.3M | −$2.0M | — |
| 2025 | 2025-03-31 | −$20.4M | −$1.7M | — |
| 2024 | 2024-03-31 | −$18.7M | −$2.4M | — |
| 2023 | 2023-03-31 | −$16.3M | — | — |
Medicenna Therapeutics quarterly ebitda
Q4.25
Q1.26
Q2.26
Q3.26
Q4.26
Q1.27
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q1 2027 | 2026-06-30 | −$5.4M | $56,000 | — |
| Q4 2026 | 2026-03-31 | −$5.8M | −$102,000 | — |
| Q3 2026 | 2025-12-31 | −$5.6M | — | — |
| Q2 2026 | 2025-09-30 | −$5.4M | — | — |
| Q1 2026 | 2025-06-30 | −$5.5M | — | — |
| Q4 2025 | 2025-03-31 | −$5.7M | — | — |
Medicenna Therapeutics ebitda trends
Between the periods ended 2023-03-31 and 2026-03-31, Medicenna Therapeutics's ebitda decreased from −$16.3M to −$22.3M, a change of −$6.0M. The latest reported quarter, Q1 2027, shows −$5.4M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Medicenna Therapeutics source filings ↗